Molbio Diagnostics IPO

Does stock fall in these catagories?: 1. Strong Recurring Revenue Model: The business operates like a printer-ink model; once the "TrueNat" machines are sold to government agencies, the company generates consistent, long-term revenue through the sale of proprietary test kits. 2. Industry Tailwinds WHO Approval: Being WHO-certified for TB diagnostics provides significant competitive moat and credibility, positioning the company as a leader in infectious disease testing. 3. High Growth Potential: The company has demonstrated strong revenue growth and is continuously investing in R&D and intellectual property patents to stay ahead of market shifts. 4. Stable Financial Foundation: The company maintains a healthy debt-to-equity ratio and positive cash flow, with significant manufacturing capacity still underutilized, allowing for future scale without massive immediate capex. Key Risks Discussed: Promoter/Investor Cashing Out: A large portion of the IPO proceeds ₹740 crore is an Offer for Sale OFS, meaning the money goes to existing shareholders rather than the company’s growth. Concentration Risk: Roughly 90% of revenue is derived from the Indian market and primarily from government contracts, creating high dependency on policy and state budgets. Commission Spikes: There has been a massive increase in commission expenses from ₹64 Cr to ₹170 Cr, which has hampered net profit margins despite revenue growth. Valuation Concerns: The IPO is priced at a premium 57x P/E, which is on par with, or higher than, established peers, leaving little "safety margin" for investors. Capacity vs. Sales Disconnect: Despite having high manufacturing capacity, sales outside India have seen a decline, raising questions about organic demand growth.